because TNFi biologics may have more sustained efficacy when used in combination with MTX, but evidence is limited 25 Active PsA despite treatment with an IL-17i biologic agent as monotherapy (Table 4 and Figure 6). All recommendations for patients with active PsA despite IL-17i biologic treatment are conditional based on very-low-quality evidence. In patients with active PsA despite treatment with an IL-17i biologic, switching to a TNFi biologic is recommended over switching to an IL-12/23i